Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breas...
Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic...
Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastati...
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% with...
In patients with hormone receptor–positive, HER2-negative advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events a...
Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of dis...
Among premenopausal patients with hormone receptor–positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on the Breast Cancer Index genomic assay had an increased ris...
Non-Hispanic Black patients with lymph node–positive, hormone receptor (HR)–positive/HER2-negative breast cancer experienced worse outcomes compared with the outcomes of non-Hispanic White, Asian, and...